TY - JOUR
T1 - Elements of nonpharmacologic interventions that prevent progression of heart failure
T2 - a meta-analysis.
AU - Kozak, Andrea T.
AU - Rucker-Whitaker, Cheryl
AU - Basu, Sanjib
AU - Mendes de Leon, Carlos F.
AU - Calvin, James E.
AU - Grady, Kathleen L.
AU - Richardson, De Juran
AU - Powell, Lynda H.
PY - 2007
Y1 - 2007
N2 - This review examined whether nonpharmacologic treatment was associated with reductions in all-cause mortality and heart failure (HF) hospitalizations and investigated the effects of face-to-face contact and longer treatment duration on these outcomes. MEDLINE and PsycINFO databases were searched through June 2006 and bibliographies of potential articles were hand-searched. Nonpharmacologic treatment was associated with significantly lower odds of HF hospitalizations (odds ratio [OR], 0.41; 95% confidence interval [CI], 0.30-0.56) and death (OR, 0.69; 95% CI, 0.56-0.85) compared with control treatment. Face-to-face contact was associated with significantly lower odds of HF hospitalization (OR, 0.42; 95% CI, 0.22-0.81; P<.05) and death (OR, 0.63; 95% CI, 0.44-0.91; P<.05) as compared with control treatment. Longer treatment duration (>or=12 months) was associated with a 65% reduction in the rate of HF hospitalizations and a 36% reduction in death rate. Nonpharmacologic treatment featuring face-to-face contact is particularly effective in reducing HF hospitalization and all-cause mortality rates.
AB - This review examined whether nonpharmacologic treatment was associated with reductions in all-cause mortality and heart failure (HF) hospitalizations and investigated the effects of face-to-face contact and longer treatment duration on these outcomes. MEDLINE and PsycINFO databases were searched through June 2006 and bibliographies of potential articles were hand-searched. Nonpharmacologic treatment was associated with significantly lower odds of HF hospitalizations (odds ratio [OR], 0.41; 95% confidence interval [CI], 0.30-0.56) and death (OR, 0.69; 95% CI, 0.56-0.85) compared with control treatment. Face-to-face contact was associated with significantly lower odds of HF hospitalization (OR, 0.42; 95% CI, 0.22-0.81; P<.05) and death (OR, 0.63; 95% CI, 0.44-0.91; P<.05) as compared with control treatment. Longer treatment duration (>or=12 months) was associated with a 65% reduction in the rate of HF hospitalizations and a 36% reduction in death rate. Nonpharmacologic treatment featuring face-to-face contact is particularly effective in reducing HF hospitalization and all-cause mortality rates.
UR - http://www.scopus.com/inward/record.url?scp=38449120693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38449120693&partnerID=8YFLogxK
U2 - 10.1111/j.1527-5299.2007.07236.x
DO - 10.1111/j.1527-5299.2007.07236.x
M3 - Article
C2 - 17917495
AN - SCOPUS:38449120693
SN - 1527-5299
VL - 13
SP - 280
EP - 287
JO - Congestive heart failure (Greenwich, Conn.)
JF - Congestive heart failure (Greenwich, Conn.)
IS - 5
ER -